Established molecular biomarkers for targeted therapies are uncommon in G/GOJ cancers with only human epidermal growth factor receptor 2 (HER2), microsatellite instable (MSI) and most recently PDL-1 status directing therapeutic options for patients. This evidence concerns the gene ERBB2 and cancer.